Tandem Diabetes Care has introduced a groundbreaking integration between its t:slim X2™ insulin pump and Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring system. This collaboration aims to provide users in the United States with enhanced flexibility and personalized diabetes management solutions.
Enhanced Compatibility for Personalized Care
The newly compatible FreeStyle Libre 3 Plus sensor offers a 15-day wear period, transmitting glucose levels every minute directly to the t:slim X2 pump. Users can access real-time glucose trends through the Tandem t:slim mobile application, providing multiple avenues for monitoring and managing their condition effectively.
Advanced Control-IQ+ Technology Integration
Powered by the latest Control-IQ+ automated insulin delivery algorithm, the t:slim X2 pump adjusts insulin dosages every five minutes based on predicted glucose values. This system uniquely features AutoBolus™, which calculates and administers correction doses for missed meals, ensuring optimal blood sugar levels are maintained consistently.
- Integration expands options for over 1 million CGM users seeking automated insulin delivery.
- 15-day sensor wear time reduces the frequency of sensor replacements, enhancing user convenience.
- AutoBolus™ feature addresses common insulin dosing challenges, improving overall diabetes management.
The collaboration marks the first step in Tandem’s strategy to link its insulin pump portfolio with Abbott’s sensor technology globally. President and CEO John Sheridan emphasized plans to extend this integration beyond the U.S. in the upcoming months, reflecting Tandem’s commitment to broadening access to advanced diabetes care technologies.
Users eligible for the early access program in the United States will receive detailed information via email, outlining the steps to integrate their devices seamlessly. Tandem aims to ensure a smooth transition for existing t:slim X2 pump users by providing necessary software updates and support.
Tandem Diabetes Care continues to lead in the field of diabetes technology, focusing on developing user-centric solutions that cater to the diverse needs of individuals managing their condition. By combining innovative insulin delivery systems with reliable continuous glucose monitoring, Tandem empowers users to achieve better health outcomes with greater ease.
Strategic partnerships like this one with Abbott not only enhance product offerings but also set a new standard for interoperability in diabetes management devices. As the landscape of diabetes technology evolves, such integrations are crucial for providing comprehensive and adaptable care options to those affected by diabetes.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
